Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD 237 (Glycopyrronium) Dose Finding in COPD
NCT00242333Phase 2Completed
- Sponsor
- Nxera Pharma
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Nxera Pharma. Primary endpoint: Trough Forced Expiratory Volume in 1 Second at 28 days. Started Oct 2005; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00242333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242333.